156 related articles for article (PubMed ID: 29983258)
41. A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy.
Favato G; Baio G; Capone A; Marcellusi A; Saverio Mennini F
Clin Ther; 2013 Jul; 35(7):904-14. PubMed ID: 23806328
[TBL] [Abstract][Full Text] [Related]
42. Human papillomavirus: science and technologies for the elimination of cervical cancer.
Bosch FX
Expert Opin Pharmacother; 2011 Oct; 12(14):2189-204. PubMed ID: 21756205
[TBL] [Abstract][Full Text] [Related]
43. Prevention of human papillomavirus (HPV)-related tumors in people living with human immunodeficiency virus (HIV).
Poljak M; Šterbenc A; Lunar MM
Expert Rev Anti Infect Ther; 2017 Nov; 15(11):987-999. PubMed ID: 29027811
[TBL] [Abstract][Full Text] [Related]
44. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.
Tay SK; Ngan HY; Chu TY; Cheung AN; Tay EH
Vaccine; 2008 Aug; 26 Suppl 12():M60-70. PubMed ID: 18945415
[TBL] [Abstract][Full Text] [Related]
45. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change.
Franco EL; Mahmud SM; Tota J; Ferenczy A; Coutlée F
Arch Med Res; 2009 Aug; 40(6):478-85. PubMed ID: 19853188
[TBL] [Abstract][Full Text] [Related]
46. Programmatic issues in the implementation of an HPV vaccination program to prevent cervical cancer.
Ault K; Reisinger K
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S26-8. PubMed ID: 18162242
[TBL] [Abstract][Full Text] [Related]
47. HPV vaccination for cervical cancer prevention is not cost-effective in Japan.
Isshiki T
Asian Pac J Cancer Prev; 2014; 15(15):6177-80. PubMed ID: 25124594
[TBL] [Abstract][Full Text] [Related]
48. Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects.
Botwright S; Holroyd T; Nanda S; Bloem P; Griffiths UK; Sidibe A; Hutubessy RCW
PLoS One; 2017; 12(10):e0182663. PubMed ID: 29016596
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH
Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249
[TBL] [Abstract][Full Text] [Related]
50. Challenges in cervical cancer prevention: a survey of U.S. obstetrician-gynecologists.
Perkins RB; Anderson BL; Gorin SS; Schulkin JA
Am J Prev Med; 2013 Aug; 45(2):175-81. PubMed ID: 23867024
[TBL] [Abstract][Full Text] [Related]
51. Human papillomavirus infection and cervical cancer prevention in Japan and Korea.
Konno R; Shin HR; Kim YT; Song YS; Sasagawa T; Inoue M; Park JS
Vaccine; 2008 Aug; 26 Suppl 12():M30-42. PubMed ID: 18945412
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
[TBL] [Abstract][Full Text] [Related]
53. Epidemiology of HPV infection and current status of cervical cancer prevention in Greece: final results of the LYSISTRATA cross-sectional study.
Agorastos T; Chatzistamatiou K; Zafrakas M; Siamanta V; Katsamagkas T; Constantinidis TC; Lampropoulos AF;
Eur J Cancer Prev; 2014 Sep; 23(5):425-31. PubMed ID: 24977385
[TBL] [Abstract][Full Text] [Related]
54. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.
Yamamoto N; Mori R; Jacklin P; Osuga Y; Kawana K; Shibuya K; Taketani Y
BJOG; 2012 Jan; 119(2):177-86. PubMed ID: 21794070
[TBL] [Abstract][Full Text] [Related]
55. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
56. The cost-utility of integrated cervical cancer prevention strategies in the Ontario setting - Can we do better?
Sander B; Wong WW; Yeung MW; Ormanidhi O; Atkin K; Murphy J; Krahn M; Deeks SL
Vaccine; 2016 Apr; 34(16):1936-44. PubMed ID: 26892739
[TBL] [Abstract][Full Text] [Related]
57. Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam.
Domingo EJ; Noviani R; Noor MR; Ngelangel CA; Limpaphayom KK; Thuan TV; Louie KS; Quinn MA
Vaccine; 2008 Aug; 26 Suppl 12():M71-9. PubMed ID: 18945416
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of the vaccine against human papillomavirus in the Brazilian Amazon region.
Fonseca AJ; Ferreira LC; Neto GB
Rev Assoc Med Bras (1992); 2013; 59(5):442-51. PubMed ID: 24041909
[TBL] [Abstract][Full Text] [Related]
59. Human Papillomavirus Vaccine as an Anticancer Vaccine: Collaborative Efforts to Promote Human Papillomavirus Vaccine in the National Comprehensive Cancer Control Program.
Townsend JS; Steele CB; Hayes N; Bhatt A; Moore AR
J Womens Health (Larchmt); 2017 Mar; 26(3):200-206. PubMed ID: 28263672
[TBL] [Abstract][Full Text] [Related]
60. The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries.
Campos NG; Sharma M; Clark A; Lee K; Geng F; Regan C; Kim J; Resch S
Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():47-56. PubMed ID: 28691334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
